Institutional members access full text with Ovid®

Share this article on:

The Effect of Intravenous Cyclosporine on Rates of Colonic Surgery in Hospitalized Patients With Severe Crohn’s Colitis

Lazarev, Mark MD*; Present, Daniel H. MD; Lichtiger, Simon MD; Kornbluth, Asher MD; Marion, James MD; Chapman, Mark MD; Ullman, Thomas A. MD

Journal of Clinical Gastroenterology: October 2012 - Volume 46 - Issue 9 - p 764–767
doi: 10.1097/MCG.0b013e31824e14a8
ALIMENTARY TRACT: Original Articles

Background: The role of intravenous (IV) cyclosporine in severe Crohn’s colitis (CC) is poorly studied.

Aim: Our primary aim was to determine the in-hospital colonic resection rate in patients with severe CC who received IV cyclosporine, and the potential predictors of resection among these patients.

Methods: An inpatient pharmacy query of all patients who received IV cyclosporine at Mount Sinai Medical Center for 12.5 years after January 1, 1996 was reviewed. Patients with CC or indeterminate colitis favoring Crohn’s were included and their medical records were reviewed. Subsequent need for colonic surgery was assessed. A Kaplan-Meier plot with log-rank testing was performed to determine the rate of colonic surgery avoidance. Forward stepwise logistic regression was performed to determine independent predictors of surgery.

Results: Forty-eight patients met our inclusion criteria. Prior thiopurine and anti-tumor necrosis factor (anti-TNF) use was 85% and 69%, respectively. The median follow-up time was 12 months (range, 1 to 60 mo). 12.5% of patients required colonic resection during their admission for IV cyclosporine. Anti-TNF use in the 4 weeks preceding IV cyclosporine was the only predictor of surgery in this setting (P=0.05). The cumulative colonic surgery avoidance rate was 72±13% at 6 months and 59±15% at 12 months.

Conclusions: The use of IV cyclosporine resulted in a low rate of in-hospitalization colonic surgery among CC patients with severe disease, the majority of whom previously failed anti-TNFs and thiopurines.

*Department of Medicine, The Harvey M. and Lyn P. Meyerhoff Inflammatory Bowel Disease Center, Division of Gastroenterology, The Johns Hopkins University Medical Institutions, Baltimore, MD

Department of Medicine, The Dr Henry D. Janowitz Division of Gastroenterology, The Mount Sinai School of Medicine, New York, NY

Dr Ullman’s work was supported by the National Institutes for Health, NIH K-08-DK069393.

The authors declare that they have nothing to disclose.

Reprints: Mark Lazarev, MD, Department of Medicine, Johns Hopkins Medicine, Division of Gastroenterology, 1830 E. Monument St., Room 420, Baltimore, MD 21287 (e-mail:

Received August 4, 2011

Accepted February 1, 2012

© 2012 Lippincott Williams & Wilkins, Inc.